POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

The US Food and Drug Administration (FDA) has granted orphan drug designation to Poolbeg’s preventive therapy for cancer ...

Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) ...

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that ...

European Commission grants orphan drug designation to Alligator Bioscience’s HLX22 to treat gastric cancer: Lund, Sweden Tuesday, May 27, 2025, 18:00 Hrs [IST] Alligator Bioscie ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ABCA4-associated ...

The London-based clinical stage biopharmaceutical company targeting diseases said the FDA has granted orphan drug designation to its POLB 001 therapy as an oral preventative treatment for T-cell ...

Ocugen ( NASDAQ: OCGN) disclosed on Tuesday that its gene therapy candidate, OCU410ST, has been granted rare pediatric ...

OCU410ST has received Rare Pediatric Disease Designation for ABCA4-associated retinopathies, potentially allowing Ocugen to ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...